Involvement of midkine in autoimmune and autoinflammatory diseases

Modern Rheumatology
Ahmet Şükrü AynacıoğluMehmet Yakup Tuna

Abstract

Midkine (MK) is a heparin-binding growth factor that markedly expressed during embryogenesis but downregulated to inconsiderable levels in healthy adults. However, MK is upregulated during tissue repair and in many pathologic conditions, mostly malignancies and inflammatory diseases. MK promotes a number of functions in target cells such as migration, proliferation, survival, growth, reproduction and repair, angiogenesis, and gene expression. It acts as a pro-inflammatory cytokine and contributes to chronic inflammation via promoting chemotaxis and tissue infiltration of neutrophils and macrophages. Furthermore, MK upregulated the production of various inflammatory mediators (i.e. interleukin (IL) 6 and IL8). Recent studies have demonstrated strong evidence that MK is involved in the onset and progression of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Sjögren's syndrome (SS) and other autoimmune conditions such as multiple sclerosis (MS). Additionally, it has been shown that MK is overexpressed in two major clinically defined forms of inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), which are classified as autoinflammatory diseas...Continue Reading

References

Jul 1, 1995·Japanese Journal of Cancer Research : Gann·K AridomeT Muramatsu
Jan 1, 1996·Annual Review of Immunology·M FeldmannR N Maini
Dec 24, 1998·Lupus·C A von MühlenM J Fritzler
Apr 25, 2000·Biochemical and Biophysical Research Communications·H MuramatsuT Muramatsu
Jun 3, 2000·Archives of Pathology & Laboratory Medicine·M KatoT Terada
Nov 18, 2000·Advances in Immunology·M C PickeringM J Walport
Sep 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·W SatoT Muramatsu
Jun 5, 2002·Current Opinion in Neurology·Bernhard HemmerNorbert Sommer
Jul 18, 2002·The Journal of Biological Chemistry·Gerald E StoicaAnton Wellstein
Sep 7, 2002·Molecular and Cellular Biology·Yoshihisa ShibataKenji Kadomatsu
Mar 12, 2004·Cancer Letters·Kenji Kadomatsu, Takashi Muramatsu
Sep 1, 2006·PLoS Medicine·Dennis McGonagle, Michael F McDermott
Nov 11, 2006·Biochemical and Biophysical Research Communications·Hideki YamamotoTakashi Muramatsu
Mar 6, 2008·Proceedings of the National Academy of Sciences of the United States of America·Jinyan WangAkio Suzumura
Aug 7, 2008·British Journal of Cancer·K OtaY Ando
Jul 3, 2009·Inflammatory Bowel Diseases·Malgorzata Krzystek-KorpackaMalgorzata Matusiewicz
Jul 9, 2009·Current Opinion in Rheumatology·Harini Bagavant, Shu Man Fu
Sep 5, 2009·Clinical Chemistry and Laboratory Medicine : CCLM·Malgorzata Krzystek-KorpackaMalgorzata Matusiewicz
Mar 23, 2010·Cell·Wendy S GarrettLaurie H Glimcher
Mar 1, 2008·Journal of Crohn's & Colitis·S P L TravisUNKNOWN European Crohn's and Colitis Organisation (ECCO)
Sep 1, 2011·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Sokratis A ApostolidisGeorge C Tsokos
Jan 12, 2012·TheScientificWorldJournal·Ludwig T WeckbachBarbara Walzog
Feb 11, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yoshifumi SonobeAkio Suzumura
Aug 24, 2012·Lancet·Daniel C Baumgart, William J Sandborn
Aug 10, 2013·Journal of the American Society of Nephrology : JASN·Maciej Lech, Hans-Joachim Anders
Sep 3, 2013·British Journal of Pharmacology·T Muramatsu
Jan 28, 2014·British Journal of Pharmacology·Hideyuki Takeuchi
Aug 8, 2015·Nature Reviews. Immunology·Calliope A DendrouManuel A Friese
May 11, 2016·Modern Rheumatology·Emiko ShindoShinichi Kawai
Jul 18, 2016·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Georg LorenzHans-Joachim Anders
Oct 25, 2016·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Pragnesh Mistry, Mariana J Kaplan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.